February 18, 2025 11:34 AM EST

Arcus touts early kidney cancer data as Gilead declines option

Max Gelman

Senior Editor

Arcus Biosciences presented new Phase 1/1b data for a kidney cancer program over the weekend and picked a dose to move forward into additional studies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Arcus touts early kidney cancer data as Gilead declines option

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy

Former FDA chief calls job cuts ‘haphazard, poorly thought-out’

Exclusive: Atomwise, a once high-flying AI startup, taps biotech vet as CEO to lead pared-down company

Pain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ar­cus touts ear­ly kid­ney can­cer da­ta as Gilead de­clines op­tion

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Arcus touts early kidney cancer data as Gilead declines option